KCNAB2

KCNAB2 encodes Kvβ2, an auxiliary subunit of voltage-gated potassium channels that binds Kv1 and Kv4 family α subunits and belongs to the aldo-ketoreductase superfamily, functioning to regulate neuronal excitability across multiple cell types (PMID:11825900, PMID:21209188, PMID:35788155). In dopamine neurons, Kvβ2 promotes surface expression of the Kv1.2 pore-forming subunit and sets the voltage dependence of channel inactivation; its loss shifts inactivation toward hyperpolarized potentials, broadens the action potential, reduces afterhyperpolarization, and increases firing irregularity and excitability (PMID:35788155). A parallel role in amygdala projection neurons, where Kvβ2 loss reduces the slow afterhyperpolarization and raises excitability, underlies deficits in associative learning and memory in knockout mice (PMID:21209188). Genetic dissection establishes that the chaperone-like and classical aldo-ketoreductase catalytic activities of Kvβ2 are dispensable for its in vivo function: channel α subunits localize and glycosylate normally without Kvβ2, and a catalytically dead Y90F knock-in shows no overt phenotype (PMID:11825900). Beyond the nervous system, KCNAB2 expression level positively regulates growth hormone secretion in pituitary somatotroph cells (PMID:32109873), and in non-small-cell lung cancer KCNAB2 acts as a tumor suppressor that inhibits PI3K/AKT-mTOR signaling, proliferation, migration, and M2 macrophage polarization while promoting apoptosis (PMID:37852974, PMID:40114527); its expression in this context is negatively controlled by FTO-mediated m6A methylation of KCNAB2 mRNA (PMID:40114527).

1. 1996 Medium

   Before functional characterization, the genomic location of human KCNAB2 was unknown; mapping it provided the anchor for subsequent disease and expression studies.

   Evidence Somatic cell hybrid mapping and FISH localizing KCNAB2 to chromosome 1p36.3

   PMID:8838324

   Open questions at the time

   • No functional or mechanistic information established
   • No link to a specific disease locus demonstrated
2. 2002 High

   It was unknown which biochemical property of Kvβ2 — its α-subunit binding, chaperone-like trafficking role, or aldo-ketoreductase catalysis — accounts for its physiological importance; genetic dissection ruled out chaperone and catalytic functions as the critical mechanism.

   Evidence Kcnab2-null and Y90F catalytic-dead knock-in mice with α-subunit immunolocalization, glycosylation analysis, and behavioral phenotyping

   PMID:11825900

   Open questions at the time

   • Did not identify the mechanism that actually drives the null phenotype
   • Cellular electrophysiological consequence not resolved in this study
3. 2011 High

   How Kvβ2 loss translates into a systems-level phenotype was unclear; linking it to reduced slow afterhyperpolarization and increased excitability in amygdala neurons connected the subunit to associative memory.

   Evidence Constitutive Kcnab2 knockout mice with associative-memory behavioral assays and whole-cell current-clamp recording in lateral amygdala neurons

   PMID:21209188

   Open questions at the time

   • Specific channel α subunit mediating the sAHP change not identified
   • Constitutive KO cannot exclude developmental compensation
4. 2022 High

   Whether Kvβ2 acts cell-autonomously in the adult to control trafficking and gating was unresolved; conditional CRISPR in adult dopamine neurons showed it sets Kv1.2 surface expression and inactivation voltage dependence to shape firing.

   Evidence Viral cell-type-specific CRISPR/Cas9 mutagenesis in dopamine neurons with Kv1.2 surface-expression assay and slice patch-clamp

   PMID:35788155

   Open questions at the time

   • Molecular basis of the inactivation voltage shift not resolved
   • Behavioral consequence of dopamine-neuron-specific loss not tested
5. 2020 Medium

   A role outside neurons was unknown; modulating Kcnab2 in somatotroph cells showed its expression level positively regulates growth hormone synthesis and secretion.

   Evidence Overexpression and shRNA knockdown of Kcnab2 in GH3 cells with GH qPCR and secreted-GH ELISA

   PMID:32109873

   Open questions at the time

   • No mechanistic pathway linking KCNAB2 to GH expression resolved
   • Single cell line, single lab
6. 2023 Medium

   Whether KCNAB2 has a role in cancer was untested; bidirectional manipulation in NSCLC defined it as a tumor suppressor acting through AKT-mTOR signaling.

   Evidence Overexpression and CRISPR knockout in NSCLC cell lines, protein chip, Western blot for AKT-mTOR, and A549 xenografts

   PMID:37852974

   Open questions at the time

   • Direct molecular link between KCNAB2 and AKT-mTOR not defined
   • Whether the effect depends on channel-associated function unknown
7. 2025 Medium

   How KCNAB2 expression is controlled in cancer and how it shapes the tumor microenvironment were open; FTO-mediated m6A methylation was shown to repress KCNAB2, whose restoration inhibits malignancy and M2 macrophage polarization via PI3K/AKT.

   Evidence m6A RIP, FTO knockdown, KCNAB2 overexpression with rescue experiments, PI3K/AKT Western blot, functional assays, and xenografts

   PMID:40114527

   Open questions at the time

   • Reader/effector linking m6A mark to KCNAB2 transcript fate not identified
   • Mechanism connecting KCNAB2 to macrophage polarization not resolved

• The molecular mechanism by which Kvβ2 governs Kv1 channel gating and trafficking in vivo — given that its chaperone and aldo-ketoreductase activities are dispensable — and how the same subunit suppresses PI3K/AKT signaling in non-neuronal cells remain unexplained.
• The functionally critical biochemical activity of Kvβ2 in vivo is unidentified
• No structural model linking subunit binding to the inactivation voltage shift
• Connection between channel-subunit role and tumor-suppressor PI3K/AKT signaling unresolved